Finally, the current study did not assess how carriers were counselled with respect to risk management strategies, for example, the absolute risk of breast and/or ovarian cancer related to pathogenic variants in BRCA1/2, morbidity of risk-reducing surgery, and the effectiveness of cancer surveillance. This evidence concerns the gene BRCA1 and ovarian cancer.